|
|||||
|
|
| 鞘氨醇-1-磷酸受体调节剂siponimod的药理作用及临床评价 | |
| 引用本文： | 杨妍妍,于立婷,史爱欣. 鞘氨醇-1-磷酸受体调节剂siponimod的药理作用及临床评价[J]. 中国新药杂志, 2020, 0(7): 726-730 |
| 作者姓名： | 杨妍妍 于立婷 史爱欣 |
| 作者单位： | 沈阳药科大学生命科学与生物制药学院;北京医院临床试验研究中心 |
| 基金项目： | 国家“重大新药创制”科技重大专项资助项目(2017ZX09304026);重大疾病新药临床评价技术平台建设课题。 |
| 摘 要： | siponimod是由诺华公司研发的一种鞘氨醇-1-磷酸受体(sphingosine-1-phosphate receptor,S1PR)调节剂,能选择性地与S1PR1和S1PR5结合,阻止淋巴细胞离开淋巴结,用于治疗成人复发型多发性硬化症,2019年3月获FDA批准上市。本文对其药理作用、药动学、临床研究及不良反应等进行归纳总结。 |
| 关 键 词： | siponimod S1PR调节剂 多发性硬化症 |
Pharmacology and clinical evaluation of sphingosine-1-phosphate receptor modulator siponimod |
|
| YANG Yan-yan,YU Li-ting,SHI Ai-xin. Pharmacology and clinical evaluation of sphingosine-1-phosphate receptor modulator siponimod[J]. Chinese Journal of New Drugs, 2020, 0(7): 726-730 | |
| Authors: | YANG Yan-yan YU Li-ting SHI Ai-xin |
| Affiliation: | (College of Life Science and Biopharmaceutics,Shenyang Pharmaceutical University,Shenyang 110016,China;Clinical Trial Center,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,P.R.China,Beijing 100730,China) |
| Abstract: | Siponimod is a sphingosine-1-phosphate receptor(S1 PR) modulator developed by Novartis that selectively binds to S1 PR1 and S1 PR5. Siponimod blocks the capacity of lymphocytes to egress from lymph nodes. Siponimod was approved by the FDA in March 2019 for the treatment of adult relapsing multiple sclerosis. This review summarizes the pharmacological effects, pharmacokinetics, clinical research and adverse reactions of siponimod. |
| Keywords: | siponimod S1PR modulator multiple sclerosis |
| 本文献已被 维普 等数据库收录！ | |